Cytek Biosciences Inc (CTKB)
Quick ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 98,716 | 162,272 | 177,918 | 169,141 | 167,630 | 163,629 | 131,544 | 129,476 | 296,601 | 341,523 | 349,894 | 362,506 | 364,618 | 376,771 | 159,846 | 168,584 | 165,231 |
| Short-term investments | US$ in thousands | 179,145 | 115,505 | 99,323 | 101,298 | 95,111 | 124,392 | 167,294 | 169,519 | 44,548 | — | — | — | — | — | — | — | — |
| Receivables | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total current liabilities | US$ in thousands | 67,663 | 62,797 | 52,379 | 55,566 | 56,226 | 58,693 | 53,591 | 56,517 | 49,040 | 41,494 | 42,350 | 42,803 | 32,160 | 29,839 | 28,165 | 27,764 | 26,536 |
| Quick ratio | 4.11 | 4.42 | 5.29 | 4.87 | 4.67 | 4.91 | 5.58 | 5.29 | 6.96 | 8.23 | 8.26 | 8.47 | 11.34 | 12.63 | 5.68 | 6.07 | 6.23 |
December 31, 2024 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($98,716K
+ $179,145K
+ $—K)
÷ $67,663K
= 4.11
The quick ratio of Cytek Biosciences Inc has shown a fluctuating trend over the past few years. The quick ratio measures the company's ability to meet its short-term obligations with its most liquid assets.
Based on the provided data:
- The quick ratio was relatively high, ranging from 5.68 to 12.63, in the fiscal year 2021, indicating a strong ability to meet short-term liabilities with quick assets.
- However, the quick ratio decreased in the fiscal year 2022, ranging from 6.96 to 8.47, suggesting a slight decrease in liquidity compared to the previous year.
- The quick ratio continued to decline in the fiscal year 2023, ranging from 4.67 to 5.58, indicating a further reduction in the ability to cover short-term obligations with quick assets.
- By the end of the fiscal year 2024, the quick ratio improved slightly but remained relatively low, ranging from 4.11 to 5.29.
Overall, the trend in the quick ratio of Cytek Biosciences Inc indicates some fluctuations in liquidity over the years, with a general decrease in the ability to cover short-term obligations with quick assets. This may be a point of concern and could require further analysis to ensure the company's financial health and stability.
Peer comparison
Dec 31, 2024